Watch the video of Professor R Marshall Austin speaking about ‘HPV-Negative Results in Women Developing Cervical Cancer: Implications for Cervical Screening Options’

The 2016 Cartwright forum was held on 5th August, and focused on ‘The Control of Cervical Cancer in New Zealand: Achievements and Prospects’. We were privileged to have Professor R Marshall Austin, Professor of Pathology and Director of Cytopathology at Magee-Womens Hospital of University of Pittsburgh Medical Center. Professor Austin spoke about the implications of moving from liquid-based cytology (LBC) to HPV-testing as the primary pathway for cervical screening, which the National Screening Unit has announced they will be introducing in 2018. Professor Austin highlighted some of the issues with HPV testing, and urged caution before embarking on an experiment with the health of New Zealand women.

Watch the video below, and see the slides from Professor Austin and the other speakers’ presentations here.
Part 1:

Part 2:

Women’s Health Action completed a submission to the National Screening Unit in October last year, and recommended that initially, co-testing should be used where both liquid-based cytology and HPV testing are done to ensure the safety and effectiveness of HPV testing. We cautioned that the use of HPV testing as the primary test needs to be thoroughly investigated in the New Zealand context using independent researchers.  Read our submission here

Professor Austin’s bio:

R. Marshall Austin, MD, PhD
University of Pittsburgh School of Medicine, Magee-Womens Hospital of UPMC
Professor of Pathology and Director of Cytopathology

Dr. Austin has been Professor of Pathology and Director of Cytopathology at Magee-Womens Hospital of University of Pittsburgh Medical Center since 2005. Currently Dr. Austin also assists educator Karyn Varley CT as Medical Director of the Anisa I. Kanbour School of Cytology.

Dr. Austin is a 1977 graduate of the Duke University School of Medicine Medical Scientist Training Program (MD, PhD) with PhD dissertation in virology. He received additional Pathology training at Duke and postgraduate subspecialty training in Gynecologic and Breast Pathology and Cytopathology from 1983-1986 at the Armed Forces Institute of Pathology. Dr. Austin’s current areas of research interest focus on cervical cancer screening, cervical neoplasia risk stratification modeling and risk management, new cervical screening technologies, and public and professional education. He is a past President of the American Society of Cytopathology (ASC) (2004-2005) and 2014 winner of the 2014 ASC Papanicolaou Award.